BD Rx announced that the FDA has approved Ondansetron Injection, the third drug from the new BD Simplist line of ready-to-administer prefilled generic injectables.
Ondansetron Injection is a 5-HT3 receptor antagonist indicated for the prevention of postoperative nausea and vomiting and with initial and repeat courses of emetogenic cancer chemotherapy.
For a traditional vial and syringe injection sequence, clinicians perform up to 20 steps, which may increase the potential risk for error. BD Simplist prefilled injectables reduce the sequence to approximately 12 steps. These ready-to-use syringes are individually packaged and are bar-coded for easy identification.
BD Rx is already manufacturing Metoclopramide Injection and Diphenhydramine Hydrochloride Injection within the BD Simplist prefilled injectables line of products. The company plans to launch 20–30 prefilled injectables in the next few years.
Ondansetron Injection will be available as a 4mg/2mL strength in a 2mL prefilled single-use syringe in a 24-count carton.
For more information call (201) 847-6800 or visit BDRxinc.com.